Aherfi, Sarah published the artcileDrug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV, Category: esters-buliding-blocks, the main research area is review COVID 19 drug repurposing SARS health; COVID-19; SARS-CoV-1; SARS-CoV-2; antiviral; coronavirus; drug repurposing; in silico; in vitro testing.
Since the beginning of the COVID-19 pandemic, large in silico screening studies and numerous in vitro studies have assessed the antiviral activity of various drugs on SARS-CoV-2. In the context of health emergency, drug repurposing represents the most relevant strategy because of the reduced time for approval by international medicines agencies, the low cost of development and the well-known toxicity profile of such drugs. Herein, we aim to review drugs with in vitro antiviral activity against SARS-CoV-2, combined with mol. docking data and results from preliminary clin. studies. Finally, when considering all these previous findings, as well as the possibility of oral administration, 11 mols. consisting of nelfinavir, favipiravir, azithromycin, clofoctol, clofazimine, ivermectin, nitazoxanide, amodiaquine, heparin, chloroquine and hydroxychloroquine, show an interesting antiviral activity that could be exploited as possible drug candidates for COVID-19 treatment.
Future Microbiology published new progress about COVID-19. 55981-09-4 belongs to class esters-buliding-blocks, name is 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate, and the molecular formula is C12H9N3O5S, Category: esters-buliding-blocks.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics